{"id":62821,"date":"2026-04-10T23:53:36","date_gmt":"2026-04-10T15:53:36","guid":{"rendered":"https:\/\/flcube.com\/?p=62821"},"modified":"2026-04-10T23:53:37","modified_gmt":"2026-04-10T15:53:37","slug":"c4-therapeutics-and-roche-forge-1b-dac-collaboration-to-pioneer-degrader-antibody-conjugates-in-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62821","title":{"rendered":"C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology"},"content":{"rendered":"\n

C4 Therapeutics, Inc.<\/strong> (NASDAQ: CCCC<\/a>), a leader in targeted protein degradation (TPD), announced an expanded strategic collaboration with Roche AG<\/strong> (SWX: ROG<\/a>; OTCMKTS: RHHBY<\/a>) to co-develop degrader-antibody conjugates (DACs)<\/strong>\u2014a novel therapeutic modality merging the precision of antibody-drug conjugates (ADCs)<\/strong> with the catalytic power of small-molecule degraders<\/strong>. The partnership targets two undisclosed oncology indications, with an option for a third, and includes up to over USD 1 billion in potential milestone payments<\/strong> plus tiered royalties for C4T.<\/p>\n\n\n\n

Deal Structure & Responsibilities<\/h2>\n\n\n\n
Component<\/th>C4 Therapeutics<\/th>Roche<\/th><\/tr><\/thead>
Technology Contribution<\/strong><\/td>Proprietary TORPEDO\u00ae<\/strong> degrader platform for payload design<\/td>Antibody discovery, conjugation, and ADC engineering<\/td><\/tr>
Development Scope<\/strong><\/td>Design of degrader payloads against two proprietary targets<\/td>Full preclinical\/clinical development and global commercialization<\/td><\/tr>
Financial Terms<\/strong><\/td>$20M upfront<\/strong> + near-term discovery milestones<\/td>Option fee for third target + regulatory\/commercial milestones<\/td><\/tr>
Total Potential Value<\/strong><\/td>> $1 billion<\/strong> across discovery, regulatory, and sales milestones<\/td>\u2014<\/td><\/tr>
Royalties<\/strong><\/td>Tiered, single-digit to low-teens % on net sales (subject to reductions)<\/td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This marks one of the first industry-wide efforts to systematically integrate PROTAC-like degraders<\/strong> into antibody-conjugate architectures<\/strong>, potentially overcoming key limitations of traditional ADCs\u2014such as payload resistance and limited bystander effect\u2014through catalytic, event-driven target elimination.<\/p>\n\n\n\n

Scientific Rationale: Why DACs?<\/h2>\n\n\n\n